AbCellera’s Single-Dose Menopause Treatment Delivers Big Reduction in Hot Flashes
AbCellera shares jumped after its menopause drug reduced hot flashes by 83% in a Phase 2 trial, with no serious side effects reported.
/ 3 items
#ABCL↓
Benchmark Upgrades AbCellera to Buy with $11 Target on Major Jazz Pharmaceuticals Partnership
AbCellera gets a boost after Jazz deal brings upfront cash and future growth potential through cancer antibody programs and milestones.
Jazz Pharmaceuticals Strikes Major Collaboration with AbCellera for Next-Generation Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors.